Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
WOODS, SCOTT W.
MARTIN, ANDRÉS
SPECTOR, STEVEN G.
and
MCGLASHAN, THOMAS H.
2002.
Effects of Development on Olanzapine-Associated Adverse Events.
Journal of the American Academy of Child & Adolescent Psychiatry,
Vol. 41,
Issue. 12,
p.
1439.
Saksa, John R.
Baker, C.Bruce
and
Woods, Scott W.
2004.
Mood-stabilizer-maintained, remitted bipolar patients: taper and discontinuation of adjunctive antipsychotic medication.
General Hospital Psychiatry,
Vol. 26,
Issue. 3,
p.
233.
Bai, Ya-Mei
Yu, Shun-Chieh
Chen, Jen-Yeu
Lin, Chih-Yuan
Chou, Pesus
and
Lin, Chao-Cheng
2005.
Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study.
International Clinical Psychopharmacology,
Vol. 20,
Issue. 2,
p.
79.
Rosenheck, Robert
2005.
The growth of psychopharmacology in the 1990s: Evidence-based practice or irrational exuberance.
International Journal of Law and Psychiatry,
Vol. 28,
Issue. 5,
p.
467.
Pierre, Joseph M
2005.
Extrapyramidal Symptoms with Atypical Antipsychotics.
Drug Safety,
Vol. 28,
Issue. 3,
p.
191.
Ragheb, Moataz M
and
Goldberg, Richard J
2006.
Tardive Dyskinesia in Geriatric Patients.
Aging Health,
Vol. 2,
Issue. 5,
p.
833.
Rosenheck, Robert A.
2007.
Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics.
British Journal of Psychiatry,
Vol. 191,
Issue. 3,
p.
238.
eLetters
No eLetters have been published for this article.